Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drug Discovery has historically been the most expensive and lengthy step in creating new drugs. SDGR's physics-based software cuts the time in half as well as the costs. Along with being a software company with 80% GMs, 99% customer retention rate and robust growth, they have their preclinical drug pipeline giving them major upside.

Schrodinger: High Margins, Sticky Business, Incredible Upside

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at two investor conferences in June.

Schrödinger to Present at Two Investor Healthcare Conferences in June

Cerecor

CRISPR Therapeutics

Horizon Pharma

Johnson & Johnson

Eli Lilly

Takeda Pharmaceutical

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

Schrödinger is a company that utilizes physics and artificial intelligence to aid in the discovery of new drug and material molecules.While the company is not yet profitable, the financials are healthy and growth is steady.

Schrödinger: Under The Radar And Brimming With Potential

Schrödinger, Inc.'s (SDGR) CEO Ramy Farid on Q1 2021 Results - Earnings Call Transcript

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 100.00% and 10.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Break-Even Earnings for Q1

Shares of Schrodinger (NASDAQ:SDGR) decreased 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.00, which beat the estimate of ($0.16).

Recap: Schrodinger Q1 Earnings

NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger reported financial results for the first quarter of 2021 and provided a company update.

Schrödinger Reports First Quarter 2021 Financial Results and Provides Company Update

Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.

Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger, Inc. (SDGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will participate in the Bank of America Securities 2021 Virtual Healthcare Conference.

Schrödinger to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

Schrodinger has done well as a company and very well as a stock since the company went public last year. Valuation multiples have expanded a great deal as investors price in the near unlimited potential of its end markets.

Schrodinger - Continued Volatility, Continued Promise

Arrival Group

Pubmatic

vTv Therapeutics

vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.

4 Up-and-Coming Stocks to Buy in Shifting Sectors

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report first quarter 2021 financial results on May 11, 2021.

Schrödinger to Host Conference Call to Discuss First Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger presented new preclinical data from its CDC7 inhibitor program during AACR 21 Annual Virtual Meeting.

Schrödinger Reports Preclinical Data on Novel, Selective CDC7 Inhibitors Presented at American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that the company will participate in the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.

Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

NEW YORK--(BUSINESS WIRE)--Schrödinger will host a webcast to review the preclinical data being presented at the AACR Annual Meeting.

Schrödinger to Host Webcast in Conjunction with Presentation of Preclinical Data for Its CDC7 Program at Virtual AACR Annual Meeting

Opendoor

Skillz

These three companies have just one thing in common: the potential to offer a long-term windfall for stockholders.

Cathie Wood Bought 3 High-Growth Tech Stocks That Could Be the Next 10-Baggers

Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor.

Cathie Wood Owns Schrodinger Stock: Should You?

NEW YORK--(BUSINESS WIRE)--Schrödinger will participate in the virtual Credit Suisse 2021 Healthcare Innovators Series on March 23, 2021.

Schrödinger to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence

This drug discovery company's stock just took a major hit.

Is There Any Hope Left for Schrodinger Stock?

NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger announced that preclinical data from its CDC7 program will be presented at the AACR Annual Meeting.

Schrödinger Announces Preclinical Data for CDC7 Program to Be Presented at AACR Virtual Annual Meeting 2021

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q4 2020 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger today reported financial results for the fourth quarter and full year 2020.

Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will provide a corporate overview during the H.C. Wainwright Global Life Sciences Conference.

News for Schrodinger Stock (SDGR)